Genomic Health (GHDX) Prelim. Q4, FY15 Revenues Miss Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Dell shares surge on record AI server bookings
- 'No panic anywhere' may be the problem, BofA strategists warn
- Kroger cuts same-store sales outlook, keeps earnings guidance
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Genomic Health (GHDX) Plans Oncotype SEQ Launch for mid-2016
January 11, 2016 8:17 AM ESTGenomic Health, Inc. (Nasdaq: GHDX) announced plans to launch its first liquid biopsy test, Oncotype SEQ, in mid-2016. The test is a blood-based mutation panel that uses next-generation sequencing to identify select actionable genomic alterations for the treatment of patients with late-stage lung, breast, colon, melanoma, ovarian or gastrointestinal cancer. As a fit-for-purpose panel, Oncotype SEQ is designed... More
Piper Jaffray Downgrades Genomic Health Inc. (GHDX) to Neutral
January 11, 2016 6:48 AM ESTPiper Jaffray downgraded Genomic Health Inc. (NASDAQ: GHDX) from Overweight to Neutral with a price target of $32.00 (from $36.00) as they shift their focus to 2017.
Analyst William Quirk commented: "We are downgrading Genomic Health on a contrarian call as we look beyond the 2016 reacceleration to 2017 expectations. We... More
